Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 13/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 10/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | TXK | P42681 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | ITK | Q08881 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1777181 | 0.94 | ESR1 (0.46) | ESR1ESR2CYP1A2ARHSD17B10 | |
| SCHEMBL10224683 | 0.81 | ESR1 (0.44) | ESR1ESR2CYP1A2ARHSD17B10 | |
| SCHEMBL12601253 | 0.79 | ESR1 (0.47) | ESR1ESR2CYP1A2ARHSD17B10 | |
| SCHEMBL9307408 | 0.78 | ESR1 (0.62) | ESR1ESR2CYP1A2ARHSD17B10 | |
| SCHEMBL20408454 | 0.76 | ESR1 (0.42) | ESR1ESR2CYP1A2ARHSD17B10 | |
| SCHEMBL18161365 | 0.76 | LMNA (0.56) | ESR1ESR2CYP1A2ARHSD17B10 | |
| SCHEMBL31015724 | 0.76 | ESR1 (0.45) | ESR1ESR2CYP1A2ARHSD17B10 | |
| SCHEMBL10040417 | 0.76 | ESR1 (0.45) | ESR1ESR2CYP1A2ARHSD17B10 | |
| SCHEMBL4379660 | 0.75 | ALDH1A1 (0.44) | ESR1ESR2HSD17B10CYP3A4TSHR | |
| SCHEMBL1777075 | 0.73 | ALOX5 (0.60) | CYP1A2HSD17B10CYP2C9CYP3A4HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943795-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2011-05-17 | — | — | US | disclosed |
| US-7943795-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2011-05-17 | — | — | US | disclosed |
| US-7943795-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2011-05-17 | — | — | US | disclosed |
| US-20090234001-A1 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY | 2009-09-17 | — | — | US | disclosed |
| US-20090234001-A1 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY | 2009-09-17 | — | — | US | disclosed |
| US-20090234001-A1 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY | 2009-09-17 | — | — | US | disclosed |
| EP-1836151-B1 | VITAMIN D RECEPTOR MODULATORS | LILLY CO ELI (US) | 2009-04-01 | — | — | EP | disclosed |
| EP-1836151-B1 | VITAMIN D RECEPTOR MODULATORS | LILLY CO ELI (US) | 2009-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234001-A1 | VITAMIN D RECEPTOR MODULATORS | VDR, CYP2R1, CYP24A1 | ESR1 521/4885ESR2 116/4885CYP1A2 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.